CONTERA PHARMA A/S: Financial statements 2019
CVR: 33062214
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
CONTERA PHARMA A/S (CVR 33062214) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -1,249,644 and a net result of DKK -2,002,844 compared with DKK -967,629 the year before. Equity in the 2019 report amounted to DKK 17,799,887. The solvency ratio was 97.7%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -1,249,644
- Profit/Loss
- DKK -2,002,844
- Equity
- DKK 17,799,887
- Total Assets
- DKK 18,224,694
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -1.2 mio. | -2 mio. | 17.8 mio. | 1 |
| 2018 | - | 1.5 mio. | -968 t. | 3.2 mio. | 2 |
| 2017 | - | 1.4 mio. | -419 t. | 1 mio. | 2 |
| 2016 | - | 3.1 mio. | 866 t. | 1.5 mio. | - |
| 2015 | - | 445 t. | -1.1 mio. | 601 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
CONTERA PHARMA A/S has published its annual report for 2018. Gross profit came to DKK 1,519,395, and the net result was DKK -967,629.
As of February 22, 2019, Jung Yoon Um has joined the board of directors of CONTERA PHARMA A/S.
On February 22, 2019, the company changed its name from CONTERA PHARMA ApS to CONTERA PHARMA A/S.
About CONTERA PHARMA A/S
CONTERA PHARMA A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CONTERA PHARMA ApS and CONCIT PHARMA ApS. The management consists of Thomas Nikolaj Sager. The board consists of Jae Young Lee (chair), Jee Hun Kim, Paul Ejnar Gremaud Kristjansen and Thomas Nikolaj Sager. The company is owned by Bukwang Pharmaceutical Co., Ltd. The company has 1 employee (2018). In 2025, the company reported a gross profit of DKK 20,632,306 and a net result of DKK -4,783,781 compared with DKK -69,213,744 the year before. Equity in the 2025 report amounted to DKK 79,471,802.